0
Rallybio Corporation Banner Image

Rallybio Corporation

  • Ticker RLYB
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Rallybio Corporation Logo Image
  • 11-50 Employees
  • Based in New Haven, Connecticut
Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolicMore disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development.
Rallybio Corporation

Most Recent Annual Report

Rallybio Corporation
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

Rallybio Corporation Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!